Table 3.
Within-group changes in primary and secondary outcomes in PTR and PR groups. Intention-to-treat principle
| Within-group changes from baseline (95% CI) | ||||
| PTR (n=67) | PR (n=67) | |||
| End rehabilitation† | 22 weeks from baseline‡ | End rehabilitation† | 22 weeks from baseline‡ | |
| Primary outcome | ||||
| 6MWD, min | 17.2 (5.8 to 28.5)* | 22.0 (5.0 to 39.1)* | 23.5 (12.1 to 35.0)* | 11.0 (−5.2 to 27.2) |
| Secondary outcomes | ||||
| 30sec-STS, reps | 1.3 (0.4 to 2.0)* | 1.1 (0.1 to 2.0)* | 1.7 (0.9 to 2.5)* | 1.5 (0.5 to 2.3)* |
| CAT, points | −1.7 (−3.2 to −0.2)* | −0.5 (−1.9 to 1.1) | −0.3 (−1.8 to 1.2) | −1.0 (−2.5 to 0.6) |
| HADS | ||||
| Anxiety, points | −1.0 (−1.7 to −0.2)* | −0.5 (−1.4 to 0.5) | 0.1 (−0.6 to 0.8) | −0.3 (−1.2 to 0.7) |
| Depression, points | −0.4 (−1.1 to 0.3) | 0.5 (−0.4 to 1.5) | 0.3 (−0.4 to 1.0) | 0.3 (−0.6 to 1.4) |
| EQ5D-VAS, points | 3.2 (−1.2 to 7.6) | 3.5 (−1.2 to 8.2) | 2.9 (−1.4 to 7.2) | 4.2 (−0.4 to 9.0) |
| CCQ | ||||
| Function, points | −0.3 (−0.5 to −0.1)* | 0.1 (−0.1 to 0.4) | −0.1 (−0.4 to 0.1) | 0.1 (−0.2 to 0.5) |
| Mental, points | −0.2 (−0.6 to 0.1) | −0.1 (−0.5 to 0.3) | −0.1 (−0.4 to 0.2) | −0.1 (−0.4 to 0.3) |
| Symptoms, points | −0.3 (−0.6 to −0.1)* | −0.2 (−0.5 to 0.1) | −0.2 (−0.4 to 0.1) | 0.1 (−0.3 to 0.5) |
| Total, points | −0.3 (−0.4 to −0.1)* | 0.0 (−0.2 to 0.2) | −0.1 (−0.3 to 0.1) | 0.1 (−0.2 to 0.3) |
| PAL | ||||
| Steps per day | −116 (−503 to 270) | −292 (−852 to 307) | −400 (−803 to −2.3)* | −594 (−1164 to −57)* |
| Sedentary, min | 29.0 (−29.9 to 95.4) | 18.8 (−11.8 to 49.3) | 38.3 (−21.7 to 107.3) | 10.1 (−21.0 to 41.3) |
| Active, min | −29.0 (−95.4 to 29.9) | −18.8 (−49.3 to 11.8) | −38.3 (−107.3 to 21.7) | −10.1 (−41.3 to 21.0) |
Data are mean difference (95% CI). Estimates adjusted for baseline outcome measure. Estimates calculated for baseline measure equal to the mean baseline measure for study population.
*P value within group changes <0.05.
†Complete observations (n) used for the likelihood estimate from end of rehabilitation to baseline (PTR/PR): 6MWD: (56/59); 30-sec STS: (56/59); CAT: (59/62); HADS: (53/57); EQ5d-VAS: (57/62); CCQ: (57/62); PAL: (30/29).
‡Complete observations (n) used for the likelihood estimate from 22 weeks’ follow-up from baseline to baseline (PTR/PR): 6MWD: (44/51); 30sec-STS: (44/51); CAT: (53/53); HADS: (50/50); EQ5d-VAS: (51/53); CCQ: (53/53); PAL: (28/27).
CAT, COPD Assessment Test; CCQ, COPD Clinical Questionnaire; EQ-5D, EuroQol 5-Dimension Questionnaire; HADS, Hospital Anxiety and Depression Scale; 6MWD, 6 min walk distance; PAL, physical activity level; PR, pulmonary rehabilitation; PTR, pulmonary tele-rehabilitation; 30sec-STS, 30 s sit-to-stand test; VAS, Visual Analogue Scale.